Session » SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1265

2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations

9:00AM-11:00AM: Abstract Number: 1290

A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 1261

Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1284

Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability

9:00AM-11:00AM: Abstract Number: 1285

Association of Frailty with Disability Is Not Attenuated by Lean Body Mass in Women with SLE

9:00AM-11:00AM: Abstract Number: 1263

Association of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and Damage Accrual in Long Standing Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1296

Associations of Metabolic Syndrome and Adipokines in SLE

9:00AM-11:00AM: Abstract Number: 1301

Characterizing How SLE Patients Access Health Information Pre and During COVID-19

9:00AM-11:00AM: Abstract Number: 1279

Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital

9:00AM-11:00AM: Abstract Number: 1274

COVID-19 in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1280

COVID-19 Infections May Increase the Risk of SLE Flares

9:00AM-11:00AM: Abstract Number: 1291

Depressed Symptomatology Persists over Time in the Majority of Systemic Lupus Erythematosus Patients and Is Independent of Disease Activity

9:00AM-11:00AM: Abstract Number: 1295

Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self-Assessments Based on Smart System of Disease Management (SSDM) Mobile Tools

9:00AM-11:00AM: Abstract Number: 1278

Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke?

9:00AM-11:00AM: Abstract Number: 1269

Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1302

Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations

9:00AM-11:00AM: Abstract Number: 1283

Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry

9:00AM-11:00AM: Abstract Number: 1293

Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database

9:00AM-11:00AM: Abstract Number: 1292

Frequency and Predictors of Influenza Vaccine Hesitancy in Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1257

Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1300

Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach

9:00AM-11:00AM: Abstract Number: 1272

Impact of Remission and Low Disease Activity Status on Hospitalizations Among SLE Patients from the GLADEL Latin American Cohort

9:00AM-11:00AM: Abstract Number: 1299

Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity

9:00AM-11:00AM: Abstract Number: 1260

Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus

9:00AM-11:00AM: Abstract Number: 1277

Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1297

Lupus Antibodies in Relation to Malignancy

9:00AM-11:00AM: Abstract Number: 1298

Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort

9:00AM-11:00AM: Abstract Number: 1264

Mortality in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms

9:00AM-11:00AM: Abstract Number: 1266

Multivariate Risk Model Shows Different Risk Factors for Myocardial Infarction and Stroke in SLE

9:00AM-11:00AM: Abstract Number: 1281

Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus

9:00AM-11:00AM: Abstract Number: 1267

Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1286

Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity

9:00AM-11:00AM: Abstract Number: 1271

Post-Traumatic Stress Disorder (PTSD) and Risk of Systemic Lupus Erythematosus (SLE) Among Medicaid Recipients

9:00AM-11:00AM: Abstract Number: 1294

Prediction of Damage in SLE Using Unbiased Analysis of Large Datasets

9:00AM-11:00AM: Abstract Number: 1288

Predictors of Frailty Identified by the Short Physical Performance Battery and Associations with Patient-reported Outcomes

9:00AM-11:00AM: Abstract Number: 1287

Prevalence of Morbidity Prior to Diagnosis of Incident Systemic Lupus Erythematosus in the Danish Population

9:00AM-11:00AM: Abstract Number: 1289

Sex Differences in Mental Health and Quality of Life and Their Impact in the Treatment of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1262

Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE

9:00AM-11:00AM: Abstract Number: 1268

Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains

9:00AM-11:00AM: Abstract Number: 1259

The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1282

The Impact of High Disease Activity as Measured by SLEDAI and Drug Burden on Healthcare Utilization, Quality of Life and Work Productivity in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1273

The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients

9:00AM-11:00AM: Abstract Number: 1258

Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1270

Trend of Survival of a Cohort of Patients with Systemic Lupus Erythematosus over 25 Years

9:00AM-11:00AM: Abstract Number: 1275

Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020

9:00AM-11:00AM: Abstract Number: 1276

Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].